Table 1

Patient characteristics

VariablesPatients with FH (n=101)Patients with NACP (n=126)p Value
Male gender62 (61%)80 (63%)0.78
Age (years)53 (7)56 (7)0.01
Risk factors
 Smoker22 (22%)41 (33%)0.03
 Diabetes§4 (4%)19 (15%)<0.01
 Hypertension25 (25%)60 (48%)<0.01
 Dyslipidaemia101 (100%)72 (57%)<0.001
 Positive family history69 (68%)58 (46%)0.001
 Body mass index (kg/m2)26 (5)25 (9)0.22
Lipids
 Total cholesterol (mmol/l)5.4 (1.2)5.0 (1.9)0.09
 LDL cholesterol (mmol/l)3.5 (1.1)3.5 (1.1)0.69
 HDL cholesterol (mmol/l)1.4 (0.4)1.3 (0.4)0.09
 Triglycerides (mmol/l)1.4 (1.2)1.6 (1.0)0.10
Lipid-related characteristics
 Maximum untreated total cholesterol (mmol/l)10.2 (2.3)6.9 (2.0)<0.001
 Known LDL mutation78 (77%)
 Xanthomas24 (24%)
 Arcus lipoides27 (27%)
 Duration of statin treatment (years)10 (8)3 (4)<0.001
 Age at start of statin treatment (years)42 (10)53 (9)<0.001
 Intense statin treatment69 (68%)4 (8%)<0.001
 Dose-limiting side effects31 (31%)3 (6%)<0.001
 Concomitant ezetimibe treatment60 (59%)5 (10%)<0.001
Calcium score
 Total calcium score* (Agatston)87 (5–367)7.3 (0–125)<0.001
 020 (20%)49 (39%)
 0–10033 (33%)42 (33%)
 >100–40024 (24%)20 (16%)
 >40024 (24%)15 (12%)0.004
  • Continuous data are expressed as mean (SD) and dichotomous data as n (%).

  • * The calcium score is expressed as median (IQR).

  • Currently and/or in the past.

  • Blood pressure >140/90 mm Hg or treatment for hypertension.

  • § Treatment with oral anti-diabetic medicine or insulin.

  • n=48, patients with NCAP treated with statins.

  • FH, familial hypercholesterolaemia; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NACP, non-anginal chest pain.